정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
149 | Completed | Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia | Covid19 | Drug: Tofacitinib 10 mg Drug: Placebo |
Phase 3 | Hospital Israelita Albert Einstein, Pfizer | OTHER | 289 | All | 18 Years | Centro de Pesquisa Clinica do Coracao, Aracaju, Brazil Hospital Universitario Sao Francisco de Assis Na Providencia de Deu, Braganca Paulista, Brazil Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Misericordia de Braganca Paulista, Braganca Paulista, Brazil Hospital do Coracao do Brasil, Brasilia, Brazil Instituto de Pesquisa Clinica de Campinas, Campinas, Brazil Hospital Regional do Litoral Norte, Caraguatatuba, Brazil Unimed Fortaleza Sociedade Corporativa Medica LTD, Fortaleza, Brazil Hospital Regional Jorge Rossmann, Itanhaem, Brazil Hospital Bruno Born, Lajeado, Brazil Hospital Sao Vicente de Paulo, Passo Fundo, Brazil Hospital Israelita Albert Einstein, Sao Paulo, Brazil Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil Hospital Regional de Registro, Sao Jose Dos Campos, Brazil Hospital Regional de Sao Jose dos Campos, Sao Jose Dos Campos, Brazil Beneficencia Portuguesa, Sao Paulo, Brazil BP Mirante, Sao Paulo, Brazil Instituto do Coracao, Sao Paulo, Brazil |
148 | Not yet recruiting | TOFAcitinib in SARS-CoV2 Pneumonia | SARS-COv2 Related Interstitial Pneumonia | Drug: Tofacitinib | Phase 2 | Universita Politecnica delle Marche | OTHER | 50 | All | 18 Years ~ 65 Years | Ospedali Riuniti di Ancona, Ancona, Marche, Italy |
147 | Not yet recruiting | TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia | COVID-19 | Drug: Tofacitinib Drug: Hydroxychloroquine |
Phase 2 | Universita Politecnica delle Marche, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Ospedale Civile Santo Spirito, Pescara, Universita Magna Grecia, Catanzaro, ASST Papa Giovanni XXIII, Bergamo, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, ASST Cremona, Cremona, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Milano, Ospedale di Circolo e Fondazione Macchi, Varese | OTHER | 116 | All | 18 Years ~ 65 Years | |
146 | Recruiting | TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19 | Covid19 | Drug: Peginterferon Lambda-1A Other: Placebo |
Phase 3 | University Health Network, Toronto | OTHER | 763 | All | 18 Years | Toronto General Hospital, Toronto, Ontario, Canada |
145 | Recruiting | Tolerability and Efficacy of RJX in Patients With COVID-19 | Hypoxemia | Drug: Rejuveinix (RJX) Active Comparator Drug: Placebo Comparator |
Phase 2 | Reven Pharmaceuticals, Inc. | INDUSTRY | 237 | All | 18 Years | Memorial Hermann Memorial City Medical Center, Houston, Texas, United States Memorial Hermann Southeast Hospital, Houston, Texas, United States Christus Santa Rosa Hospital, New Braunfels, Texas, United States |
144 | Completed | Topical Lidocaine Anesthesia for Nasopharyngeal Sampling | Local Anesthesia | Drug: Lidocaine Other: Placebo |
Not Applicable | Ataturk University | OTHER | 50 | All | 18 Years ~ 65 Years | Ataturk University, Erzurum, Turkey |
143 | Not yet recruiting | Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis | Keratonjunctivitis | Drug: topical steroids and cyclosporin-A | Not Applicable | Ameera Gamal Abdelhameed, Ministry of Health, Kuwait | OTHER | 12 | All | Farawanyia hospital, Kuwait, Farawanyia, Kuwait |